19.1(top 1%)
impact factor
1.8K(top 10%)
papers
109.0K(top 5%)
citations
157(top 2%)
h-index
19.9(top 1%)
extended IF
2.0K
all documents
125.0K
doc citations
227(top 5%)
g-index

Top Articles

#TitleJournalYearCitations
1Ferroptosis, a new form of cell death: opportunities and challenges in cancerJournal of Hematology and Oncology20191,081
2Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applicationsJournal of Hematology and Oncology2019949
3The biology and role of CD44 in cancer progression: therapeutic implicationsJournal of Hematology and Oncology2018888
4Ferroptosis, necroptosis, and pyroptosis in anticancer immunityJournal of Hematology and Oncology2020785
5Targeting the Wnt/β-catenin signaling pathway in cancerJournal of Hematology and Oncology2020775
6The effects of β-glucan on human immune and cancer cellsJournal of Hematology and Oncology2009676
7Tumor-associated macrophages: from basic research to clinical applicationJournal of Hematology and Oncology2017656
8Next generation of immune checkpoint therapy in cancer: new developments and challengesJournal of Hematology and Oncology2018640
9Exosomes in cancer: small particle, big playerJournal of Hematology and Oncology2015634
10Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancersJournal of Hematology and Oncology2013618
11Targeting mTOR for cancer therapyJournal of Hematology and Oncology2019614
12Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapyJournal of Hematology and Oncology2019597
13Nanomaterials for cancer therapy: current progress and perspectivesJournal of Hematology and Oncology2021593
14Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinomaJournal of Hematology and Oncology2015566
15SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19Journal of Hematology and Oncology2020535
16EZH2: a novel target for cancer treatmentJournal of Hematology and Oncology2020526
17Immune checkpoint inhibitors of PD-L1 as cancer therapeuticsJournal of Hematology and Oncology2019515
18Wnt/beta-catenin pathway: modulating anticancer immune responseJournal of Hematology and Oncology2017494
19Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacyJournal of Hematology and Oncology2019447
20Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancerJournal of Hematology and Oncology2020424
21Role of platelets and platelet receptors in cancer metastasisJournal of Hematology and Oncology2018421
22A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaJournal of Hematology and Oncology2018407
23The interplay between m6A RNA methylation and noncoding RNA in cancerJournal of Hematology and Oncology2019407
24Clinical applications of mesenchymal stem cellsJournal of Hematology and Oncology2012406
25Long non-coding RNA: a new player in cancerJournal of Hematology and Oncology2013393
26Mechanism of action of lenalidomide in hematological malignanciesJournal of Hematology and Oncology2009383
27Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical developmentJournal of Hematology and Oncology2018377
28Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsJournal of Hematology and Oncology2010376
29NK cell-based cancer immunotherapy: from basic biology to clinical developmentJournal of Hematology and Oncology2021376
30An evolving new paradigm: endothelial cells – conditional innate immune cellsJournal of Hematology and Oncology2013363
31Functions of lncRNA HOTAIR in lung cancerJournal of Hematology and Oncology2014361
32Nanotechnology in cancer diagnosis: progress, challenges and opportunitiesJournal of Hematology and Oncology2019351
33Regulation of PD-L1 expression in the tumor microenvironmentJournal of Hematology and Oncology2021350
34Next generation of immune checkpoint inhibitors and beyondJournal of Hematology and Oncology2021350
35Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapyJournal of Hematology and Oncology2019333
36Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumorsJournal of Hematology and Oncology2016324
37Abscopal effect of radiotherapy combined with immune checkpoint inhibitorsJournal of Hematology and Oncology2018324
38Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 proteinJournal of Hematology and Oncology2017321
39Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trialJournal of Hematology and Oncology2017318
40Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucelJournal of Hematology and Oncology2018318
41Roles of METTL3 in cancer: mechanisms and therapeutic targetingJournal of Hematology and Oncology2020316
42Challenges and advances in clinical applications of mesenchymal stromal cellsJournal of Hematology and Oncology2021313
43Diverse functions of miR-125 family in different cell contextsJournal of Hematology and Oncology2013312
44A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancerJournal of Hematology and Oncology2013310
45CircRNAs in cancer metabolism: a reviewJournal of Hematology and Oncology2019310
46Targeting the IDO1 pathway in cancer: from bench to bedsideJournal of Hematology and Oncology2018306
47cGAS-STING, an important pathway in cancer immunotherapyJournal of Hematology and Oncology2020302
48New development in CAR-T cell therapyJournal of Hematology and Oncology2017301
49M6A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinomaJournal of Hematology and Oncology2020301
50Emerging therapies for small cell lung cancerJournal of Hematology and Oncology2019300